🎬 kick off - day Università degli Studi di Milano-Bicocca RT department for the new SGRT-based LINAC 🎯 that’s one big step for 👨‍⚕️, one giant leap for our patients ! Regione Lombardia AIRO Radioterapia_Oncologica AIOM

Thoughtful work by Stephen Chun, Jeff Bradley, MD and NRG Oncology on the importance of radiation dose compactness, cardiac and lung sparing approaches to improve outcome in unresectable locally advanced #NSCLC. Minimizing 🫁 V20 Gy matters, minimizing ❤️ V40 Gy matters (20-60 Gy).

Just out! MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-…

Great to see this new updated guideline on oncogene-addicted metastatic NSCLC from ESMO - Eur. Oncology

Congratulations to the new board members of ASTRO! Recognition of tireless representative work 😁 #radonc

The JTO & JTO CRR has published the fully formatted manuscript for our resectable NSCLC consensus! Have a look and see what you think: jto.org/article/S1556-… Perhaps most notable from my perspective was the high level of agreement between the expert panel and the external

Probably yes! All these high-quality data on heart, esophagus, BM etc. are rapidly changing the whole approach to standard constraints and DVHs in thoracic RT and beyond

Great two day discussion at OncLive.com Bridging the Gap in #lungcancer learning from our thoracic surgical and thoracic medical oncology colleagues. Appreciate the open discussion on controversies and unmet needs to help our patients. Kristin Higgins Hari B. Keshava

Key insights from #ESTRO24 on optimising radiation doses for stage III #NSCLC with #immunotherapy and TKIs. Learn about dose escalation trials, individualised treatment strategies, and biomarker roles in therapy guidance. 👉 bit.ly/3SFzayz IASLC #radonc #radiotherapy

Federico Mastroleo Stronger together💪🏻💪🏻💪🏻

Please share this fundraiser to support her family with the #oncTwitter and #radonc community. gofundme.com/f/honoring-dr-… 🙏Lucy Kalanithi UNC Department of Radiation Oncology ASTRO ARRO ACRO - American College of Radiation Oncology Tatiana Prowell, MD Mark Lewis, MD, FASCO SWRO Stephanie Graff, MD, FACP, FASCO Narjust Florez, MD, FASCO Don S. Dizon MD (he/him) 🇬🇺 H. Jack West, MD, FASCO Ishwaria Subbiah, MD MS FASCO

Drew Moghanaki 🐕 Shankar Siva BTOG David Baldwin Corinne Faivre-Finn 💙 Fiona McDonald Sanjay Popat Haval Balata Jonathan Spicer MD PhD donington Patrick Forde M.Provencio Really thought provoking. It fits with the staging discordance as reported in the Seismic study led by Daniel Steinfort Shankar Siva and colleagues at Peter Mac Cancer Centre . It’s hard to hit the target when you don’t know where it is…🎯

Rushing to publish? Let's slow down and make every paper count. Quality beats quantity every time.

Important study ➡️one-third of patients with stage IIIN2 single station based CT, PETCT and EBUS staging actually have multistation N2 ➡️🤔definition of resectability should not be based on single vs multiple station Matthew Evison IASLC EORTC

Vuoi conoscere meglio il Reparto di Radioterapia dell'Istituto Nazionale dei Tumori di Milano? In questo video, il Prof. Andrea Filippi, Direttore del Reparto, racconta le attività e i servizi offerti ai pazienti. youtu.be/ENYPxU6jMA0?si… #IstitutoTumoriMilano #Radioterapia

So many great #WCLC24 sessions to choose from. Sunday September 8th, at 2pm, global experts weigh in on their approach to #EGFR NSCLC and discuss role of 1L combinations. With Drs. Culligan, Zosia Piotrowska Roberto Ferrara Victor Marcondes Sewanti Limaye 🇮🇳🇺🇸 Curioni_Oncology_MD, Koichi Goto

Happy to share the IEO RADIOSA results. Time for short combined treatment in oligorecurrent HSPC? Brava Giulia! Giulia Marvaso Zach Klaassen

Keynote 867, which investigated Pembrolizumab in stage I and II NSCLC after SBRT, was closed early due to futility. ➡️This underscores the critical need for phase 3 trials, as promising phase 2 results do not always translate into clinical benefit in phase 3

"the long-term survival of patients with CRC pulmonary oligometastases did not depend on the initial choice of the local treatment approach" #radonc redjournal.org/article/S0360-…

pubmed.ncbi.nlm.nih.gov/25542308/